Aseptic processing contamination case studies and the pharmaceutical quality system

PDA Journal of Pharmaceutical Science and Technology

Volumn 59, Issue 2, 2005, Pages 118-126

  Friedman, Richard L ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS ACTING ON THE EYE; PARENTERAL SOLUTION;

ACINETOBACTER; ASEPSIS; BACTERIUM CONTAMINATION; DRUG CONTAMINATION; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG PACKAGING; DRUG STERILITY; ENTEROBACTER CLOACAE; ENVIRONMENTAL FACTOR; EQUIPMENT; FOOD AND DRUG ADMINISTRATION; GOOD MANUFACTURING PRACTICE; MEMBRANE FILTER; PERSONNEL; PSEUDOMONAS; QUALITY CONTROL; REVIEW; STENOTROPHOMONAS MALTOPHILIA;

ASEPSIS; DRUG CONTAMINATION; DRUG INDUSTRY; EQUIPMENT CONTAMINATION; HUMANS; QUALITY CONTROL;

EID: 25144485364     PISSN: 10797440     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. US Food & Drug Administration. Guidance on Sterile Drug Products Produced by Aseptic Processing, September, 2004.
2. Annex 1, Manufacture of Sterile Medicinal Products, European Union GMPs, European Commission, 2003.
3. Block, S. S. Disinfection, Sterilization, and Preservation, 5th Edition. Lippincott, Williams and Wilkins: Philadelphia, PA, 2000.
4. Parenteral Drug Association. Process Simulation Testing for Aseptically Filled Products; Technical Report No. 22, 1996.
5. Parenteral Drug Association. Sterilizing Filtration of Liquids; Technical Report No. 26., 1998.
6. Ljungqvist, B.; Reinmuller, B. Clean Room Design: Minimizing Contamination Through Proper Design. Interpharm Press: Buffalo Grove, IL, 1997.
7. Oji, R. T. Regulatory aspects concerning the quality controls of microbiological and non-viable particulate contamination in pharmaceutical manufacturing. American Pharmaceutical Review 2004, 7(1), 18-22, 68.
8. Matthews, Brian R. The Davonport Incident, the Clothier Report, and Related Matters-30 Years On. PDA Journal of Pharmaceutical Science & Technology. 2002, 56 (3), 137-149
9. Avallone, H. Current regulatory issues regarding parenteral inspections. Journal of Parenteral Science and Technology 1989, 43(1), 3-7
10. "Sterility Requirement for Aqueous-Based Drug Products for Oral Inhalation," Final Rule 21 CFR 200.51, Federal Register May 26, 2000 65 (FR 34082).
11. FDA Recalls and Safety Alerts, http://www.fd-a.gov/opacom/7alerts.html
12. Snyder J. E. Corrective and preventive action planning to achieve sustainable GMP compliance. Journal of GXP Compliance 2002, 6(3), 29-39.
13. Baseline Pharmaceutical Engineering Guide for Sterile Manufacturing Facilities, International Society for Pharmaceutical Engineering 1999, 3 (January)
14. Friedman, R.; Mahoney, S. Risk factors in aseptic processing. American Pharmaceutical Review 2003, 6(1), page 44-46, 92.
15. Massa, T. Life Cycle Management for Process and System Control: An Industry Proposal. Manufacturing Subcommittee, Advisory Committee for Pharmaceutical Science. July 20, 2004.
16. 21 CFR 210 and 211, US Food & Drug Administration, US Printing Office.
17. Food & Drug Administration. Compliance Program Guidance Manual - Drug Manufacturing Inspections, CPGM 7356.002, February 2002.
18. Famulare, J. Quality Systems Guidance. PDA/FDA Joint Regulatory Conference, Washington, DC, September 2004.
19. US Food & Drug Administration. Draft Guidance on Quality Systems Approach to Pharmaceutical Current Good Manufacturing Practice Regulations. September 2004.
20. Friedman, R. Routes of contamination: aseptic processing case studies. European Journal of Parenteral & Pharmaceutical Sciences 2005, 10(1), 3-7.
21. Goode, R.; Evans, K. The scientific method: application to FDA regulated industry. Part I of III. Journal of Validation Technology 2003, 10(1), 37-43.
22. US Food & Drug Administration. Sec. 490.100, Process Validation Requirements for Drug Products and Active Pharmaceutical Ingredients Subject to Pre-Market Approval (CPG 7132c.08), March, 2004.
23. Cooper, J.; Bruegger, P.; Fanning, M.; Matsuura, S.; Poole, S. "Alert and Action Endotoxin Levels for APIs: A Collaborative Study." Parenteral Drug Association Annual Meeting, December 2002.
24. Vesper, J. L. Chapter 19. Training and Learning: Critical Contributors to Quality. In Pharmaceutical Quality; Prince, R., Ed.; DHI Publishing: River Grove, IL, 2004.
25. FDA Advisory Committee for Pharmaceutical Science, October 22, 2002.
26. Lysford, J.; Porter. M. Barrier Isolation History and Trends. International Society for Pharmaceutical Engineering Washington Conference: Barrier Isolation Technology, June 2004.
27. th Pharmaceutical Isolator Conference, Warwick, U.K., December 2004.
28. Wood, R. T. Sterilization of API manufacturing equipment. PDA Journal of Pharmaceutical Science & Technology 1999, 53(5), 231-234
29. Sinclair, C. S.; Tallentire, A. Performance of blow/fill/seal equipment under controlled airborne microbial challenges. PDA Journal of Pharmaceutical Science & Technology 1995, 49(6), 294-299.
30. Khorzad, D.; Khorzad, A.; Herche, J.; Reich, M.; Caputo, R. Design and operational qualification of a vapor-phase hydrogen peroxide biological indicator evaluator resistometer (BIER) unit. Pharmaceutical Technology 2003, 84-90
31. Woodcock, J. The concept of pharmaceutical quality. American Pharmaceutical Review 2004, 7(6), 10-15.
32. Food & Drug Administration. Pharmaceutical cGMPs for the 21st Century - A Risk-Based Approach, Final Report, September 2004.
33. Friedman, R. Chapter 3: Quality Management in the American Pharmaceutical Industry. In Pharmaceutical Quality; Prince, R., Ed.; DHI Publishing: River Grove, IL, 2004.
34. Dwyer, T.; Keresty, G.; Sherry, B. "The cost of non-conformance: the linkage between quality performance and business results. Pharmaceutical Engineering 2001, 20(5), 8-14.